As a promising synthetic peptide, Felypressin finds extensive applications in the realms of dental and medical procedures. Its vasoconstrictor properties enable efficacious mitigation of hemorrhages, thereby garnering immense attention for surgical and treatment interventions. Dentistry, in particular, embraces Felypressin fervently, harnessing its attributes as a potent local anesthetic to effectively address periodontal ailments and proffer optimum soothing for individuals enduring discomfort.
CAT No: R2009
CAS No: 56-59-7
Synonyms/Alias: FELYPRESSIN;PLV-2;56-59-7;Felypressine;Felypressinum;Felipressina;Felipresina;Felipressina [DCIT];2-(L-Phenylalanine)-8-L-lysinevasopressin;Felipresina [INN-Spanish];Felypressine [INN-French];Felypressinum [INN-Latin];Phe(2)-Lys(8)-vasopressin;Felypressin [USAN:INN:BAN];DTXSID6048599;UNII-17N2918V6G;CHEBI:60564;EINECS 200-282-7;DTXCID6028525;Vasopressin, 2-L-phenylalanine-8-L-lysine-;17N2918V6G;(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide;Felipresina (INN-Spanish);Felypressine (INN-French);Felypressinum (INN-Latin);FELYPRESSIN (MART.);FELYPRESSIN [MART.];1-{[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-lysylglycinamide;L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide;FELYPRESSIN (EP IMPURITY);FELYPRESSIN [EP IMPURITY];FELYPRESSIN (EP MONOGRAPH);FELYPRESSIN [EP MONOGRAPH];Phenylalanyl-Lysyl Vasopressin;Vasopressin, Phenylalanyl Lysyl;Lysine Vasopressin, Phenylalanine;Vasopressin, Phenylalanine Lysine;NCGC00182033-01;1-(((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-L-prolyl-L-lysylglycinamide;FELYPRESSIN [MI];FELYPRESSIN [INN];SCHEMBL33291;FELYPRESSIN [WHO-DD];PLV-2 (TN);CHEMBL3185126;SFKQVVDKFKYTNA-DZCXQCEKSA-N;HY-A0182;Tox21_112932;AKOS030529558;CS-5837;DB00093;CAS-56-59-7;DA-63405;FF138109;NS00033543;A12648;CYS-PHE-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (1-6 DISULFIDE);CYS-PHE-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (1-6 DISULPHIDE);(S)-N-((S)-6-amino-1-((2-amino-2-oxoethyl)amino)-1-oxohexan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide;200-282-7;L-CYSTEINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LYSYLGLYCINAMIDE CYCLIC (1->6)DISULPHIDE;
Chemical Name: (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C46H65N13O11S2 |
M.W/Mr. | 1040.2 |
Sequence | One Letter Code:CFFQNCPKG Three Letter Code:H-Cys(1)-Phe-Phe-Gln-Asn-Cys(1)-Pro-Lys-Gly-NH2 |
Appearance | Solid |
InChI | InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 |
InChI Key | SFKQVVDKFKYTNA-DZCXQCEKSA-N |
Canonical SMILES | C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)NC(CCCCN)C(=O)NCC(=O)N |
Isomeric SMILES | C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N |
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.